Genetic testing that shows inherited cancer risk and how a patient's genes may affect which drugs and doses fit them.
Consented intake · your records travel with you · nothing moves without your sign-off
Invitae offers genetic testing for hereditary cancer syndromes, including BRCA1/2, Lynch syndrome, and other inherited cancer risks. It also provides pharmacogenomic testing for drug-gene interactions, showing whether a patient carries genes that would argue for avoiding a drug or adjusting its dose. It is for patients and families who want inherited risk and drug response information to inform care decisions.
Prefer the source? Invitae's own site has more.
The fastest way to know what you'll pay: check your coverage with your plan. Below is what we know about how Invitae handles billing.
Accepted
In-network carriers
Invitae accepts insurance; In-network carriers include Medicare. Add your plan on OpenCancer to check coverage before you commit.
Through OpenCancer's consented intake: enter your details once, choose exactly which records travel with the request, and sign a consent that covers this connection only. Nothing is shared without your sign-off.
Answers grounded in Invitae's details here. Educational only; your oncologist directs treatment.
Powered by Navis on opencancer.ai
Cancer types served
Other providers in similar categories.
FoundationOne CDx is an FDA-approved comprehensive genomic profiling test that analyzes 324 genes to identify clinically relevant genomic alterations.
Tempus xT is a comprehensive genomic profiling test combining DNA and RNA sequencing to identify actionable mutations.
Caris Molecular Intelligence provides comprehensive tumor profiling to match patients with targeted therapies and clinical trials.
Gather distinctive biomarkers that can guide treatment and monitor disease progression
This page is general information. Upload your records for analysis specific to YOUR diagnosis.